Scientists Discover Antibody that Blocks Infection by the SARS-CoV-2 in Cells
Researchers at Utrecht University, Erasmus Medical Center and Harbour BioMed (HBM) today reported that they have identified a fully human monoclonal antibody that prevents the SARS-CoV-2 (COVID-19) virus from infecting cultured cells.
The discovery, published online in Nature Communications, is an initial step towards developing a fully human antibody to treat and prevent the respiratory disease COVID-19 caused by the novel coronavirus SARS-CoV-2.
The COVID-19 pandemic has spread rapidly across the globe, infecting more than 3.3 million people worldwide and killing more than 235,000 people so far.
Read Also: Homemade Mask with Evening Gown Fabric is As Good As N95 Mask?
Advertisement
[the_ad id=”6394″]
“This research builds on the work our group have done in the past on antibodies targeting the SARS-CoV that emerged in 2002/2003,” tai Berend-Jan Bosch, Associate Professor, Research leader at Utrecht University, and co-lead author of the Nature Communications study.
“Using this collection of SARS-CoV antibodies, we identified an antibody that also neutralises infection of SARS-CoV-2 in cultured cells. Such a neutralising antibody has potential to alter the course of infection in the infected host, support virus clearance or protect an uninfected individual that is exposed to the virus.”
Dr. Bosch noted that the antibody binds to a domain that is conserved in both SARS-CoV and SARS-CoV-2, explaining its ability to neutralise both viruses.
Read Also: Nonsurgical Treatment Options Effective for Sinus Issues, Study Shows
“This cross-neutralising teature of the antibody is very interesting and suggests it may have potential in mitigation of disease caused by future-emerging related coronaviruses.”
This discovery provides a strong foundation for additional research to characterise this antibody and begin development as a potential COVID-19 treatment,” said Frank Grosveld, PhD, co-lead author on the study, Academy Professor of Cell Biology, Erasmus Medical Center, Rotterdam and Founding Chief Scientific Officer at Harbour BioMed.
“The antibody used in this work is ‘fully human’, allowing development to proceed more rapidly and reducing the potential for immune-related side effects.”
Read Also: Almost All Economic Sectors, Businesses can Reopen on 4 May, Subject to Conditions
Conventional therapeutic antibodies are first developed in other species and then must undergo additional work to ‘humanise’ them. The antibody was generated using Harbour BioMed’s H2L2 transgenic mouse technology.
“This is groundbreaking research,” said Dr Jingsong Wang, Founder, Chairman & Chief Executive Officer of HBM. “Much more work is needed to assess whether this antibody can protect or reduce the severity of disease in humans.”
“We expect to advance development of the antibody with partners. We believe our technology can contribute to addressing the most urgent public health need and we are pursuing several other research avenues.”
Read Also: WHO Receives Nearly 1,300 Entries for Inaugural ‘Health for All’ Film Festival
CITATION
Utrecht University. “Antibody blocks infection by the SARS-CoV-2 in cells, scientists discover.” ScienceDaily. ScienceDaily, 4 May 2020. <www.sciencedaily.com/releases/2020/05/200504074722.htm>.
